Pathophysiology of Multiple Myeloma Bone Disease

Suzanne Lentzsch, Lori A. Ehrlich, G. David Roodman

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.

Original languageEnglish (US)
Pages (from-to)1035-1049
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume21
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Bone Diseases
Multiple Myeloma
Bone Development
Osteoclasts
Osteoblasts
Bone Remodeling
Plasma Cells
Osteogenesis
Bone and Bones
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Pathophysiology of Multiple Myeloma Bone Disease. / Lentzsch, Suzanne; Ehrlich, Lori A.; Roodman, G. David.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1035-1049.

Research output: Contribution to journalArticle

Lentzsch, Suzanne ; Ehrlich, Lori A. ; Roodman, G. David. / Pathophysiology of Multiple Myeloma Bone Disease. In: Hematology/Oncology Clinics of North America. 2007 ; Vol. 21, No. 6. pp. 1035-1049.
@article{fa9f8e82d8554293b8dd381090daf7a5,
title = "Pathophysiology of Multiple Myeloma Bone Disease",
abstract = "Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.",
author = "Suzanne Lentzsch and Ehrlich, {Lori A.} and Roodman, {G. David}",
year = "2007",
month = "12",
doi = "10.1016/j.hoc.2007.08.009",
language = "English (US)",
volume = "21",
pages = "1035--1049",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Pathophysiology of Multiple Myeloma Bone Disease

AU - Lentzsch, Suzanne

AU - Ehrlich, Lori A.

AU - Roodman, G. David

PY - 2007/12

Y1 - 2007/12

N2 - Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.

AB - Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=35748959381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748959381&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2007.08.009

DO - 10.1016/j.hoc.2007.08.009

M3 - Article

C2 - 17996587

AN - SCOPUS:35748959381

VL - 21

SP - 1035

EP - 1049

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -